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Background
One of the targets of a future multi-component vaccine
against HIV-1 should be one of the virus' chief mucosal
penetration processes, namely epithelial transcytosis. We
further reported that fusion proteins based on the mem-
brane proximal region (MPR) of gp41, playing a key role
in the transcytotic process, and the mucosal targeting sub-
unit B of cholera toxin (CTB) are successful immunogens
eliciting such transcytosis blocking immune responses
and that such proteins can be produced in plants
Methods
Here, we report on the molecular characterization of CTB-
MPR expressed in bacteria and transgenic plants and its
immunological properties.
Results
We show that bacterially and plant-produced CTB-MPR
can be purified to homogeneity. The MPR domain could
specifically and reversibly self-associate. The affinities of
the mAbs 4E10 and 2F5 to CTB-MPR from either source
were equivalent to their affinities toward an MPR peptide.
The fusion protein's affinity to GM1-ganglioside was com-
parable to that of native CTB. Mice and rabbits immu-
nized with CTB-MPR shwoed modest anti-MPR antibody
response, but a prime-boost immunization with CTB-
MPR and a second MPR-based immunogen elicited a
stronger response. These Abs strongly blocked the epithe-
lial transcytosis of primary clade B and D isolates in a
human tight epithelial model. The Abs recognized
epitopes at the N-terminal portion of the MPR peptide,
away from the neutralizing epitopes and were not effec-
tive in neutralizing infection of CD4+ cells. These results
indicate distinct vulnerabilities of two separate interac-
tions of HIV-1 with human cells – Abs against the C-ter-
minal portion of the MPR can neutralize CD4+-
dependent infection, while Abs targeting the MPR's N-ter-
minal portion can effectively block GalCer-dependent
transcytosis
Conclusion
We conclude that Abs induced by MPR-based immuno-
gens may provide broad protective value independent of
infection neutralization and that plant-based expression
can be a viable alternative for the production of subunit
HIV-1 vaccine candidates.
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